Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

SUPPLEMENTAL NOTICE OF THE POSTPONED ANNUAL GENERAL MEETING

REFERENCES ARE MADE TO the circular (the "**Original Circular**") of Genscript Biotech Corporation (the "**Company**") and the notice of the annual general meeting (the "**AGM**") of the Company (the "**Original Notice**") both dated 22 April 2024, and the announcement of the Company dated 16 May 2024, in relation to, among other things, the postponement of the AGM. This supplemental notice should be read together with the Original Notice.

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the AGM originally scheduled to be held at Conference Room, 208 Longmian Avenue, Jiangning District, Nanjing, Jiangsu Province, PRC on Friday, 17 May 2024 at 9:30 a.m. is rescheduled and postponed to Friday, 21 June 2024 at 8:30 a.m. (U.S. Eastern Time) at Conference Room, 860 Centennial Avenue, Piscataway, New Jersey, United States of America (the "**Postponed AGM**") to consider and, if thought fit, approve the following resolution as ordinary resolution in addition to the resolution set out in the Original Notice:

ORDINARY RESOLUTION

2(A)(vi) To re-elect Dr. Wang Luquan as non-executive Director.

By Order of the Board
Genscript Biotech Corporation
Meng Jiange
Chairman

Hong Kong, 30 May 2024

Registered office:
4th Floor, Harbour Place
103 South Church Street
George Town, P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

Principal place of business in Hong Kong:
40th Floor, Dah Sing Financial Centre
No. 248 Queen's Road East
Wanchai
Hong Kong

* *For identification purposes only*

Notes:

(i) Details of the above resolution is set out in the supplemental circular of the Company dated 30 May 2024 (the "**Supplemental Circular**").

(ii) A second proxy form (the "**Second Proxy Form**") containing the additional ordinary resolution numbered 2A(vi) is enclosed with the Supplemental Circular. Please refer to the section headed "**3. SUPPLEMENTAL NOTICE OF THE POSTPONED AGM AND SECOND PROXY FORM**" on pages 5 to 6 of the Supplemental Circular for arrangements on the completion and submission of the Second Proxy Form.

(iii) For determining the entitlement of Shareholders to attend and vote at the Postponed AGM, the register of members of the Company will be closed from Tuesday, 18 June 2024 to Friday, 21 June 2024, both days inclusive, during which period no transfer of shares will be registered. In order to be eligible to attend and vote at the Postponed AGM, all transfers of shares documents, accompanied by the relevant share certificates, must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for registration no later than 4:30 p.m. on Monday, 17 June 2024.

(iv) Please refer to the Original Notice for details of the other ordinary resolutions to be considered at the Postponed AGM.

(v) Whether or not the Shareholders are able to attend the Meeting in person, the Shareholders are required to complete the Second Proxy Form in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong.

(vi) The Shareholders are reminded that return of the First Proxy Form and/or the Second Proxy Form will not preclude the Shareholders from attending and voting in person at the Meeting or any adjournment thereof should they so wish.

(vii) Unless otherwise stated, all dates and times mentioned in this supplemental notice refer to Hong Kong dates and times.

As at the date of this supplemental notice, the Board comprises Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li as executive Directors, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen as non-executive Directors and Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan, Dr. Wang Xuehai, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang as independent non-executive Directors.